These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33197651)

  • 1. Loss of HCRP1 leads to upregulation of PD-L1 via STAT3 activation and is of prognostic significance in EGFR-dependent cancer.
    Tomasich E; Topakian T; Heller G; Udovica S; Krainer M; Marhold M
    Transl Res; 2021 Apr; 230():21-33. PubMed ID: 33197651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HCRP1 downregulation promotes hepatocellular carcinoma cell migration and invasion through the induction of EGFR activation and epithelial-mesenchymal transition.
    Xu J; Zhang X; Wang H; Ge S; Gao T; Song L; Wang X; Li H; Qin Y; Zhang Z
    Biomed Pharmacother; 2017 Apr; 88():421-429. PubMed ID: 28122307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased HCRP1 promotes breast cancer metastasis by enhancing EGFR phosphorylation.
    Yang W; Wang JG; Wang Q; Qin Y; Lin X; Zhou D; Ren K; Hou C; Xu J; Liu X
    Biochem Biophys Res Commun; 2016 Aug; 477(2):222-8. PubMed ID: 27311861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased HCRP1 expression is associated with poor prognosis in breast cancer patients.
    Xu J; Yang W; Wang Q; Zhang Q; Li X; Lin X; Liu X; Qin Y
    Int J Clin Exp Pathol; 2014; 7(11):7915-22. PubMed ID: 25550832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer.
    Sun L; Lü J; Ding S; Bi D; Ding K; Niu Z; Liu P
    Biomed Pharmacother; 2017 Jul; 91():202-207. PubMed ID: 28458158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Up-regulation of HCRP1 inhibits proliferation and invasion in glioma cells via suppressing the ERK and AKT signaling pathways.
    Xu CY; Li ZJ; Hu WZ
    Biomed Pharmacother; 2017 Nov; 95():31-36. PubMed ID: 28826094
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HCRP1 inhibits cell proliferation and invasion and promotes chemosensitivity in esophageal squamous cell carcinoma.
    Wu Y; Yang Y; Xian YS
    Chem Biol Interact; 2019 Aug; 308():357-363. PubMed ID: 31152734
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interleukin-22 attenuates double-stranded RNA-induced upregulation of PD-L1 in airway epithelial cells via a STAT3-dependent mechanism.
    Seki N; Kan-O K; Matsumoto K; Fukuyama S; Hamano S; Tonai K; Ota K; Inoue H; Nakanishi Y
    Biochem Biophys Res Commun; 2017 Dec; 494(1-2):242-248. PubMed ID: 29032197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma.
    Li T; Zhang C; Zhao G; Zhang X; Hao M; Hassan S; Zhang M; Zheng H; Yang D; Liu L; Mehraein-Ghomi F; Bai X; Chen K; Zhang W; Yang J
    Cancer Lett; 2020 May; 477():19-30. PubMed ID: 32120023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The growth-regulatory protein HCRP1/hVps37A is a subunit of mammalian ESCRT-I and mediates receptor down-regulation.
    Bache KG; Slagsvold T; Cabezas A; Rosendal KR; Raiborg C; Stenmark H
    Mol Biol Cell; 2004 Sep; 15(9):4337-46. PubMed ID: 15240819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HCRP-1 regulates EGFR-AKT-BIM-mediated anoikis resistance and serves as a prognostic marker in human colon cancer.
    Chen F; Zhang L; Wu J; Huo F; Ren X; Zheng J; Pei D
    Cell Death Dis; 2018 Dec; 9(12):1176. PubMed ID: 30518879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
    Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
    Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
    [No Abstract]   [Full Text] [Related]  

  • 13. Overexpressed ITGA2 promotes malignant tumor aggression by up-regulating PD-L1 expression through the activation of the STAT3 signaling pathway.
    Ren D; Zhao J; Sun Y; Li D; Meng Z; Wang B; Fan P; Liu Z; Jin X; Wu H
    J Exp Clin Cancer Res; 2019 Dec; 38(1):485. PubMed ID: 31818309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALIX Regulates Tumor-Mediated Immunosuppression by Controlling EGFR Activity and PD-L1 Presentation.
    Monypenny J; Milewicz H; Flores-Borja F; Weitsman G; Cheung A; Chowdhury R; Burgoyne T; Arulappu A; Lawler K; Barber PR; Vicencio JM; Keppler M; Wulaningsih W; Davidson SM; Fraternali F; Woodman N; Turmaine M; Gillett C; Franz D; Quezada SA; Futter CE; Von Kriegsheim A; Kolch W; Vojnovic B; Carlton JG; Ng T
    Cell Rep; 2018 Jul; 24(3):630-641. PubMed ID: 30021161
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous targeted kinase inhibitors treatment induces upregulation of PD-L1 in resistant NSCLC.
    Jiang L; Guo F; Liu X; Li X; Qin Q; Shu P; Li Y; Wang Y
    Sci Rep; 2019 Mar; 9(1):3705. PubMed ID: 30842489
    [TBL] [Abstract][Full Text] [Related]  

  • 16. HCRP1 expression status is a significant prognostic marker in oral and oropharyngeal cancer.
    Perisanidis C; Savarese-Brenner B; Würger T; Wrba F; Huynh A; Schopper C; Kornek G; Selzer E; Ewers R; Psyrri A; Krainer M; Filipits M
    Oral Dis; 2013 Mar; 19(2):206-11. PubMed ID: 22891969
    [TBL] [Abstract][Full Text] [Related]  

  • 17. hVps37A Status affects prognosis and cetuximab sensitivity in ovarian cancer.
    Wittinger M; Vanhara P; El-Gazzar A; Savarese-Brenner B; Pils D; Anees M; Grunt TW; Sibilia M; Holcmann M; Horvat R; Schemper M; Zeillinger R; Schöfer C; Dolznig H; Horak P; Krainer M
    Clin Cancer Res; 2011 Dec; 17(24):7816-27. PubMed ID: 22016507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RAS-Mitogen-Activated Protein Kinase Signal Is Required for Enhanced PD-L1 Expression in Human Lung Cancers.
    Sumimoto H; Takano A; Teramoto K; Daigo Y
    PLoS One; 2016; 11(11):e0166626. PubMed ID: 27846317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
    Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
    Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
    [No Abstract]   [Full Text] [Related]  

  • 20. An IL-27/Stat3 axis induces expression of programmed cell death 1 ligands (PD-L1/2) on infiltrating macrophages in lymphoma.
    Horlad H; Ma C; Yano H; Pan C; Ohnishi K; Fujiwara Y; Endo S; Kikukawa Y; Okuno Y; Matsuoka M; Takeya M; Komohara Y
    Cancer Sci; 2016 Nov; 107(11):1696-1704. PubMed ID: 27564404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.